- Home
- AIRS vs ACIU Comparison
AIRS vs ACIU Comparison
Compare AIRS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- ACIU
- Stock Information
- Founded
- AIRS 2012
- ACIU 2003
- Country
- AIRS United States
- ACIU Switzerland
- Employees
- AIRS N/A
- ACIU N/A
- Industry
- AIRS Medical/Nursing Services
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- ACIU Health Care
- Exchange
- AIRS Nasdaq
- ACIU Nasdaq
- Market Cap
- AIRS 334.6M
- ACIU 305.7M
- IPO Year
- AIRS 2021
- ACIU 2016
- Fundamental
- Price
- AIRS $8.66
- ACIU $3.20
- Analyst Decision
- AIRS Hold
- ACIU Strong Buy
- Analyst Count
- AIRS 3
- ACIU 2
- Target Price
- AIRS $5.50
- ACIU $12.00
- AVG Volume (30 Days)
- AIRS 152.4K
- ACIU 87.8K
- Earning Date
- AIRS 11-08-2024
- ACIU 11-05-2024
- Dividend Yield
- AIRS N/A
- ACIU N/A
- EPS Growth
- AIRS N/A
- ACIU N/A
- EPS
- AIRS N/A
- ACIU N/A
- Revenue
- AIRS $188,780,000.00
- ACIU $48,505,404.00
- Revenue This Year
- AIRS N/A
- ACIU N/A
- Revenue Next Year
- AIRS $11.17
- ACIU $938.44
- P/E Ratio
- AIRS N/A
- ACIU N/A
- Revenue Growth
- AIRS N/A
- ACIU 4097200.00
- 52 Week Low
- AIRS $2.92
- ACIU $2.25
- 52 Week High
- AIRS $8.88
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- AIRS 67.15
- ACIU 51.42
- Support Level
- AIRS $5.68
- ACIU $2.80
- Resistance Level
- AIRS $7.00
- ACIU $3.12
- Average True Range (ATR)
- AIRS 0.48
- ACIU 0.16
- MACD
- AIRS 0.14
- ACIU 0.03
- Stochastic Oscillator
- AIRS 74.80
- ACIU 83.33
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.